Proteomic-based stratification of intermediate-risk prostate cancer patients
Zhong Q, Sun R, Aref A, Noor Z, Anees A, Zhu Y, Lucas N, Poulos R, Lyu M, Zhu T, Chen G, Wang Y, Ding X, Rutishauser D, Rupp N, Rueschoff J, Poyet C, Hermanns T, Fankhauser C, Martínez M, Shao W, Buljan M, Neumann J, Beyer A, Hains P, Reddel R, Robinson P, Aebersold R, Guo T, Wild P. Proteomic-based stratification of intermediate-risk prostate cancer patients. Life Science Alliance 2023, 7: e202302146. PMID: 38052461, PMCID: PMC10698198, DOI: 10.26508/lsa.202302146.Peer-Reviewed Original ResearchConceptsGleason grade groupBiochemical recurrenceRisk of biochemical recurrenceIntermediate-risk patientsNon-aggressive diseaseProstate cancer managementProstate cancer patientsMultivariate Cox regressionHigh-risk groupPatient treatment decisionsProstatic adenocarcinomaGleason gradePrognostic indicatorMatched tumorCancer managementCox regressionCancer patientsGrade groupTreatment decisionsPatientsSurvival analysisRisk scoreClinical applicationGleasonProstate